Alx Oncology Holdings (ALXO)
Alx Oncology Holdings on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
6.0M
Short interest
settlement 2026-10-15
3.6
Days to cover
-0.2 days vs prior
67.8%
Short share of volume
2026-11-03
17
Fails to deliver
settlement 2026-09-17
Fri 6 Nov
Next earnings
estimated date
-$5K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ALXO is 5,976,398 shares, down 297,254 shares over the last month. Over the last 48 readings it ranged from 793,867 shares (28 November 2025) to 8,394,637 shares (13 December 2024). At the reported average volume of 1.6M shares a day that is 3.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/alxo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,976,398 | +5.3% | 1,645,881 | 3.63 |
| 2026-09-30 | 5,673,137 | -9.6% | 1,495,736 | 3.79 |
| 2026-09-15 | 6,273,652 | -11.2% | 805,352 | 7.79 |
| 2026-08-31 | 7,064,802 | -7.2% | 575,105 | 12.28 |
| 2026-08-14 | 7,612,189 | -1.4% | 1,571,588 | 4.84 |
| 2026-07-31 | 7,718,258 | +3.5% | 581,146 | 13.28 |
| 2026-07-15 | 7,460,211 | +18.1% | 1,131,789 | 6.59 |
| 2026-06-30 | 6,318,290 | +144.0% | 3,060,345 | 2.06 |
| 2026-06-15 | 2,589,032 | +51.8% | 980,863 | 2.64 |
| 2026-05-29 | 1,705,895 | +23.6% | 1,283,230 | 1.33 |
| 2026-05-15 | 1,380,136 | -37.5% | 713,775 | 1.93 |
| 2026-04-30 | 2,206,868 | +7.9% | 1,183,029 | 1.87 |
| 2026-04-15 | 2,045,874 | -8.0% | 1,192,708 | 1.72 |
| 2026-03-31 | 2,222,798 | +81.7% | 768,037 | 2.89 |
| 2026-03-13 | 1,223,050 | +4.3% | 513,111 | 2.38 |
| 2026-02-27 | 1,172,124 | -0.2% | 968,784 | 1.21 |
| 2026-02-13 | 1,174,673 | +3.5% | 1,088,382 | 1.08 |
| 2026-01-30 | 1,135,216 | +4.5% | 413,360 | 2.75 |
| 2026-01-15 | 1,086,386 | +10.3% | 273,938 | 3.97 |
| 2025-12-31 | 985,188 | -6.0% | 146,258 | 6.74 |
| 2025-12-15 | 1,047,613 | +32.0% | 212,826 | 4.92 |
| 2025-11-28 | 793,867 | -55.4% | 236,484 | 3.36 |
| 2025-11-14 | 1,780,683 | -3.5% | 455,947 | 3.91 |
| 2025-10-31 | 1,844,412 | -0.9% | 341,167 | 5.41 |
| 2025-10-15 | 1,860,704 | +38.8% | 628,235 | 2.96 |
| 2025-09-30 | 1,340,930 | -15.0% | 941,728 | 1.42 |
| 2025-09-15 | 1,577,840 | -13.2% | 394,442 | 4.00 |
| 2025-08-29 | 1,817,847 | +11.3% | 2,955,591 | 1.00 |
| 2025-08-15 | 1,632,590 | -63.5% | 429,122 | 3.80 |
| 2025-07-31 | 4,475,437 | +1.9% | 621,565 | 7.20 |
| 2025-07-15 | 4,389,742 | -9.9% | 411,219 | 10.67 |
| 2025-06-30 | 4,874,545 | -10.3% | 788,439 | 6.18 |
| 2025-06-13 | 5,437,599 | -4.5% | 464,758 | 11.70 |
| 2025-05-30 | 5,690,931 | -2.3% | 396,434 | 14.36 |
| 2025-05-15 | 5,827,016 | -3.7% | 488,225 | 11.94 |
| 2025-04-30 | 6,049,167 | -1.5% | 514,407 | 11.76 |
| 2025-04-15 | 6,138,898 | -2.5% | 575,369 | 10.67 |
| 2025-03-31 | 6,295,707 | -1.4% | 473,978 | 13.28 |
| 2025-03-14 | 6,388,348 | +8.5% | 2,293,004 | 2.79 |
| 2025-02-28 | 5,887,074 | -8.7% | 414,536 | 14.20 |
| 2025-02-14 | 6,446,434 | +7.7% | 690,953 | 9.33 |
| 2025-01-31 | 5,988,123 | -23.5% | 1,535,672 | 3.90 |
| 2025-01-15 | 7,830,371 | +3.0% | 775,089 | 10.10 |
| 2024-12-31 | 7,599,378 | -9.5% | 1,394,277 | 5.45 |
| 2024-12-13 | 8,394,637 | +17.1% | 1,360,039 | 6.17 |
| 2024-11-29 | 7,171,358 | -0.8% | 757,834 | 9.46 |
| 2024-11-15 | 7,225,229 | -7.9% | 827,837 | 8.73 |
| 2024-10-31 | 7,842,727 | -18.2% | 858,981 | 9.13 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of ALXO volume is 67.8%, up 45.7 points over the last five sessions. Over the last 30 readings it ranged from 18.1% (28 October 2026) to 84.5% (22 October 2026). The latest reading is 17.8 points above the 30-session average of 50.0%, on 267K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 181K | 267K | 67.8% | 0 |
| 2026-11-02 | 329K | 627K | 52.5% | 1,471 |
| 2026-10-30 | 118K | 151K | 78.0% | 0 |
| 2026-10-29 | 483K | 707K | 68.3% | 0 |
| 2026-10-28 | 345K | 1.9M | 18.1% | 0 |
| 2026-10-27 | 408K | 1.8M | 22.1% | 0 |
| 2026-10-26 | 492K | 592K | 83.1% | 0 |
| 2026-10-23 | 175K | 250K | 70.0% | 0 |
| 2026-10-22 | 176K | 208K | 84.5% | 0 |
| 2026-10-21 | 120K | 447K | 26.9% | 1,987 |
| 2026-10-20 | 131K | 268K | 48.8% | 0 |
| 2026-10-19 | 191K | 319K | 59.9% | 0 |
| 2026-10-16 | 473K | 952K | 49.7% | 100 |
| 2026-10-15 | 1.2M | 3.1M | 39.4% | 0 |
| 2026-10-14 | 344K | 1.3M | 25.6% | 33,710 |
| 2026-10-13 | 220K | 417K | 52.8% | 20,429 |
| 2026-10-12 | 183K | 352K | 51.8% | 970 |
| 2026-10-09 | 147K | 402K | 36.5% | 0 |
| 2026-10-08 | 222K | 561K | 39.6% | 0 |
| 2026-10-07 | 185K | 326K | 56.7% | 0 |
| 2026-10-06 | 255K | 452K | 56.5% | 640 |
| 2026-10-05 | 334K | 690K | 48.3% | 0 |
| 2026-10-02 | 412K | 826K | 49.9% | 0 |
| 2026-10-01 | 190K | 508K | 37.4% | 0 |
| 2026-09-30 | 207K | 349K | 59.3% | 0 |
| 2026-09-29 | 322K | 649K | 49.5% | 0 |
| 2026-09-28 | 317K | 822K | 38.6% | 0 |
| 2026-09-25 | 158K | 419K | 37.8% | 0 |
| 2026-09-24 | 200K | 475K | 42.2% | 35,939 |
| 2026-09-23 | 177K | 371K | 47.8% | 1,041 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 17 September 2026, the fails-to-deliver balance in ALXO is 17 shares, down 14,837 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (4 February 2026) to 680,406 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-17 | 17 | $1.76 | $30 |
| 2026-09-02 | 14,854 | $1.98 | $29K |
| 2026-08-21 | 39 | $1.99 | $78 |
| 2026-08-14 | 8,546 | $1.94 | $17K |
| 2026-08-12 | 4,536 | $1.93 | $9K |
| 2026-08-11 | 14 | $2.06 | $29 |
| 2026-08-06 | 1,679 | $1.92 | $3K |
| 2026-08-04 | 2,271 | $1.93 | $4K |
| 2026-07-31 | 252 | $1.95 | $491 |
| 2026-07-30 | 3 | $1.95 | $6 |
| 2026-07-28 | 1,428 | $2.02 | $3K |
| 2026-07-21 | 1,989 | $1.92 | $4K |
| 2026-07-20 | 30 | $2.10 | $63 |
| 2026-07-16 | 735 | $2.03 | $1K |
| 2026-07-08 | 10,000 | $2.36 | $24K |
| 2026-07-01 | 64,094 | $2.07 | $133K |
| 2026-06-30 | 680,406 | $2.20 | $1.5M |
| 2026-06-29 | 675,006 | $2.04 | $1.4M |
| 2026-06-18 | 331,048 | $1.45 | $480K |
| 2026-06-10 | 321 | $1.55 | $498 |
| 2026-06-04 | 406 | $1.67 | $678 |
| 2026-04-16 | 100,000 | $1.68 | $168K |
| 2026-03-25 | 2,762 | $2.04 | $6K |
| 2026-03-24 | 25,059 | $2.20 | $55K |
| 2026-03-18 | 7,365 | $2.17 | $16K |
| 2026-03-12 | 2,074 | $2.15 | $4K |
| 2026-02-04 | 1 | $1.87 | $2 |
| 2026-01-09 | 41,950 | $1.24 | $52K |
| 2026-01-08 | 33,700 | $1.18 | $40K |
| 2026-01-07 | 17,500 | $1.08 | $19K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ALXO reported 2 open-market sells worth $5K in the last 90 days and no open-market buys. Latest filing: Lettmann Jason (CHIEF EXECUTIVE OFFICER) on 2026-08-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Sell | 2K | $1.93 | $4K | 294K |
| 2026-08-17 | Wong Shelly | SVP, FINANCE AND CAO | Sell | 573 | $1.93 | $1K | 88K |
| 2026-07-01 | Wong Shelly | SVP, FINANCE AND CAO | Sell | 1K | $2.04 | $3K | 88K |
| 2026-03-19 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Sell | 12K | $2.17 | $27K | 294K |
| 2026-03-19 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 903 | $2.17 | $2K | 87K |
| 2026-02-18 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 565 | $2.27 | $1K | 88K |
| 2026-02-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Tax withholding | 2K | $2.27 | $5K | 306K |
| 2026-02-02 | GOODMAN COREY S | Director, 10% owner | Buy | 3.2M | $1.57 | $5.0M | 8.5M |
| 2026-01-06 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 4K | $1.11 | $4K | 88K |
| 2025-09-17 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Buy | 71K | $1.08 | $77K | 305K |
| 2025-09-16 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Buy | 21K | $1.07 | $22K | 234K |
| 2025-08-18 | Shantharam Harish | Chief Financial Officer | Buy | 75K | $0.78 | $58K | 75K |
| 2025-08-15 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 611 | $0.64 | $391 | 89K |
| 2025-08-15 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Sell | 2K | $0.64 | $2K | 213K |
| 2025-07-07 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 2K | $0.45 | $905 | 87K |
| 2025-06-30 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 2K | $0.43 | $659 | 89K |
| 2025-03-14 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Grant | 42K | $0.00 | $0 | 212K |
| 2025-03-14 | Pinto Shelly | SVP, FINANCE AND CAO | Grant | 3K | $0.00 | $0 | 90K |
| 2025-02-19 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Sell | 2K | $1.15 | $2K | 170K |
| 2025-02-19 | Pons Jaume | PRESIDENT & CSO | Sell | 1K | $1.15 | $2K | 579K |
| 2025-02-19 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 550 | $1.15 | $633 | 87K |
| 2025-01-06 | Pinto Shelly | Interim CFO | Sell | 2K | $1.80 | $4K | 88K |
| 2024-12-30 | Pons Jaume | PRESIDENT & CSO | Sell | 11K | $1.58 | $17K | 581K |
| 2024-12-30 | Pinto Shelly | Interim CFO | Sell | 1K | $1.58 | $2K | 90K |
| 2024-12-02 | Hemrajani Rekha | Director | Buy | 30K | $1.55 | $47K | 33K |
| 2024-08-14 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Tax withholding | 2K | $2.58 | $6K | 169K |
| 2024-08-14 | Pons Jaume | PRESIDENT & CSO | Sell | 2K | $2.58 | $5K | 592K |
| 2024-08-14 | GARCIA PETER S | CHIEF FINANCIAL OFFICER | Tax withholding | 761 | $2.58 | $2K | 122K |
| 2024-08-14 | Randolph Sophia | CHIEF MEDICAL OFFICER | Sell | 1K | $2.58 | $4K | 326K |
| 2024-08-14 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 564 | $2.58 | $1K | 92K |
| 2024-07-11 | Pons Jaume | PRESIDENT & CSO | Exercise or conversion | 20K | $0.99 | $20K | 613K |
| 2024-07-11 | Pons Jaume | PRESIDENT & CSO | Sell | 20K | $7.90 | $158K | 593K |
| 2024-07-05 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 2K | $5.50 | $10K | 92K |
| 2024-07-01 | Pons Jaume | PRESIDENT & CSO | Sell | 11K | $5.82 | $63K | 593K |
| 2024-07-01 | Randolph Sophia | CHIEF MEDICAL OFFICER | Sell | 3K | $5.82 | $19K | 327K |
| 2024-07-01 | Pinto Shelly | SVP, FINANCE AND CAO | Sell | 1K | $5.82 | $8K | 94K |
| 2024-06-28 | GARCIA PETER S | CHIEF FINANCIAL OFFICER | Tax withholding | 2K | $6.03 | $11K | 122K |
| 2024-06-13 | GARCIA PETER S | CHIEF FINANCIAL OFFICER | Buy | 12K | $8.53 | $102K | 122K |
| 2024-06-04 | Pons Jaume | PRESIDENT & CSO | Sell | 20K | $8.43 | $169K | 604K |
| 2024-06-04 | Pons Jaume | PRESIDENT & CSO | Exercise or conversion | 20K | $0.99 | $20K | 624K |
| 2024-05-13 | Randolph Sophia | CHIEF MEDICAL OFFICER | Sell | 2K | $16.67 | $30K | 330K |
| 2024-05-13 | Randolph Sophia | CHIEF MEDICAL OFFICER | Sell | 10K | $15.82 | $161K | 332K |
| 2024-05-06 | Pons Jaume | PRESIDENT & CSO | Sell | 20K | $15.92 | $318K | 604K |
| 2024-05-06 | Pons Jaume | PRESIDENT & CSO | Exercise or conversion | 20K | $0.99 | $20K | 624K |
| 2024-04-16 | Pons Jaume | PRESIDENT & CSO | Sell | 50K | $14.20 | $710K | 604K |
| 2024-04-16 | Pons Jaume | PRESIDENT & CSO | Exercise or conversion | 26K | $0.99 | $26K | 654K |
| 2024-04-04 | Pons Jaume | PRESIDENT & CSO | Sell | 20K | $11.15 | $223K | 628K |
| 2024-03-14 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Buy | 4K | $11.31 | $50K | 172K |
| 2024-02-14 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | Grant | 60K | $0.00 | $0 | 167K |
| 2024-02-14 | Pons Jaume | PRESIDENT & CSO | Grant | 30K | $0.00 | $0 | 648K |
| 2024-02-14 | Randolph Sophia | CHIEF MEDICAL OFFICER | Grant | 30K | $0.00 | $0 | 342K |
| 2024-02-14 | GARCIA PETER S | CHIEF FINANCIAL OFFICER | Grant | 25K | $0.00 | $0 | 110K |
| 2024-02-14 | Pinto Shelly | SVP, FINANCE AND CAO | Grant | 15K | $0.00 | $0 | 94K |
| 2024-01-04 | Pinto Shelly | SVP, Finance and CAO | Sell | 3K | $13.60 | $37K | 79K |
| 2023-12-29 | Pons Jaume | President & CSO | Sell | 7K | $15.04 | $108K | 618K |
| 2023-12-29 | GARCIA PETER S | Chief Financial Officer | Sell | 2K | $15.04 | $28K | 85K |
| 2023-12-29 | Randolph Sophia | Chief Medical Officer | Sell | 3K | $15.04 | $47K | 312K |
| 2023-12-29 | Pinto Shelly | SVP, Finance and CAO | Sell | 2K | $15.04 | $25K | 81K |
| 2023-07-25 | Pons Jaume | President & CEO | Grant | 89K | $0.00 | $0 | 626K |
| 2023-07-25 | GARCIA PETER S | Chief Financial Officer | Grant | 32K | $0.00 | $0 | 87K |
| 2023-07-25 | Pinto Shelly | SVP, Finance and CAO | Grant | 26K | $0.00 | $0 | 82K |
| 2023-07-25 | Randolph Sophia | Chief Medical Officer | Grant | 34K | price not stated in the filing | not stated | 315K |
| 2023-07-06 | Pinto Shelly | VP, Finance and CAO | Sell | 7K | $6.52 | $48K | 56K |
| 2023-06-30 | GARCIA PETER S | Chief Financial Officer | Sell | 887 | $7.34 | $7K | 55K |
| 2023-06-30 | Pinto Shelly | VP, Finance and CAO | Sell | 466 | $7.34 | $3K | 63K |
| 2023-06-30 | Pons Jaume | President & CEO | Sell | 3K | $7.34 | $24K | 537K |
| 2023-06-30 | Randolph Sophia | Chief Medical Officer | Sell | 2K | $7.34 | $12K | 281K |
| 2023-06-09 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 3K | $4.08 | $10K | 277K |
| 2023-06-09 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 6K | $4.81 | $30K | 283K |
| 2023-06-09 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 4K | $1.91 | $8K | 274K |
| 2022-12-29 | Pons Jaume | President & CEO | Sell | 3K | $11.07 | $36K | 540K |
| 2022-12-29 | GARCIA PETER S | Chief Financial Officer | Sell | 893 | $11.07 | $10K | 54K |
| 2022-12-29 | Randolph Sophia | Chief Medical Officer | Sell | 2K | $11.07 | $18K | 270K |
| 2022-12-29 | Pinto Shelly | VP, Finance and CAO | Sell | 482 | $11.07 | $5K | 62K |
| 2022-12-16 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 13K | $4.08 | $52K | 247K |
| 2022-12-16 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 8K | $1.91 | $16K | 234K |
| 2022-12-16 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 25K | $4.81 | $122K | 272K |
| 2022-08-05 | Pons Jaume | President & CEO | Grant | 74K | $0.00 | $0 | 543K |
| 2022-08-05 | GARCIA PETER S | Chief Financial Officer | Grant | 29K | $0.00 | $0 | 55K |
| 2022-08-05 | Pinto Shelly | VP, Finance and CAO | Grant | 11K | $0.00 | $0 | 63K |
| 2022-08-05 | Randolph Sophia | Chief Medical Officer | Grant | 37K | $0.00 | $0 | 225K |
| 2022-02-07 | GARCIA PETER S | Chief Financial Officer | Exercise or conversion | 7K | $4.08 | $27K | 16K |
| 2022-02-07 | GARCIA PETER S | Chief Financial Officer | Exercise or conversion | 8K | $4.81 | $40K | 24K |
| 2022-02-03 | Pons Jaume | President & CEO | Exercise or conversion | 12K | $0.99 | $12K | 457K |
| 2022-02-03 | Pons Jaume | President & CEO | Exercise or conversion | 12K | $1.91 | $23K | 469K |
| 2022-01-28 | Pinto Shelly | VP, Finance and CAO | Grant | 50K | $0.00 | $0 | 50K |
| 2021-12-15 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 13K | $0.99 | $13K | 177K |
| 2021-12-15 | Randolph Sophia | Chief Medical Officer | Exercise or conversion | 11K | $1.91 | $21K | 188K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 2K | $28.37 | $62K | 2.1M |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 299 | $28.37 | $8K | 286K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 1K | $29.60 | $39K | 2.1M |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 60 | $30.23 | $2K | 286K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 2K | $25.29 | $41K | 290K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 440 | $30.23 | $13K | 2.1M |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 1K | $27.49 | $36K | 286K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 10K | $27.49 | $261K | 2.1M |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 2K | $26.48 | $62K | 288K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 17K | $26.48 | $455K | 2.1M |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 181 | $29.60 | $5K | 286K |
| 2021-12-13 | Lightstone Ventures II (A), L.P. | TenPercentOwner | Sell | 12K | $25.29 | $302K | 2.1M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of ALXO in their latest filing, 5 on Schedule 13D (active intent). The largest reported stake is GOODMAN COREY S at 10.0% of the class (12,927,442 shares), filed 2026-10-16 for an event on 2026-10-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-16 | 13D/Ano. 2 | GOODMAN COREY Sindividual, parent holding company | 12.9M | 10.0% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 2 | venBio Global Strategic Fund II L.P.partnership | 8.5M | 6.5% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 2 | venBio Global Strategic GP II, Ltd.corporation | 8.5M | 6.5% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 2 | venBio Global Strategic GP II, L.P.partnership | 8.5M | 6.5% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 2 | venBio Global Strategic GP, Ltd.corporation | 4.3M | 3.3% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 2 | venBio Global Strategic GP, L.P.partnership | 4.3M | 3.3% | 2026-10-14 |
| 2026-10-16 | 13D/Ano. 2 | venBio Global Strategic Fund, L.P.partnership | 4.3M | 3.3% | 2026-10-14 |
| 2026-08-14 | 13G/Ano. 1 | Chen Yuindividual | 5.7M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TCG Crossover GP II, LLCother entity | 2.8M | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TCG Crossover Fund II, L.P.partnership | 2.8M | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TCG Crossover GP III, LLCother entity | 2.8M | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TCG Crossover Fund III, L.P.partnership | 2.8M | 2.1% | 2026-06-30 |
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 7.3M | 5.4% | 2026-06-30 |
| 2026-05-27 | 13D/Ano. 3 | Michael A Carusiindividual | 2.9M | 2.2% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | Henry A. Plain Jrindividual | 2.9M | 2.2% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | Jean Georgeindividual | 2.9M | 2.2% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | LSV Associates, LLCother entity | 1.5M | 1.2% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | Lightstone Ventures II, L.P.partnership | 1.3M | 1.0% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | Lightstone Ventures, L.P.partnership | 1.4M | 1.0% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | LSV Associates II, LLCother entity | 1.4M | 1.0% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | Lightstone Ventures II (A), L.P.partnership | 78K | 0.1% | 2026-05-27 |
| 2026-05-27 | 13D/Ano. 3 | Lightstone Ventures (A), L.P.partnership | 186K | 0.1% | 2026-05-27 |
| 2026-05-15 | 13G/Ano. 3 | Redmile Group, LLCinvestment adviser, other entity | 9.2M | 6.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Jeremy C. Greenparent holding company, individual | 9.2M | 6.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Redmile Biopharma Investments III, L.P.partnership | 5.3M | 3.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | HBM Healthcare Investments (Cayman) Ltd.corporation | 8.6M | 6.5% | 2026-03-31 |
| 2026-04-28 | 13G/Ano. 2 | Millennium Management LLCother entity | 2.0M | 1.5% | 2026-03-31 |
| 2026-04-28 | 13G/Ano. 2 | Millennium Group Management LLCother entity | 2.0M | 1.5% | 2026-03-31 |
| 2026-04-28 | 13G/Ano. 2 | Israel A. Englanderindividual | 2.0M | 1.5% | 2026-03-31 |
| 2026-04-28 | 13G/Ano. 2 | Integrated Core Strategies (US) LLCother entity | 731K | 0.5% | 2026-03-31 |
| 2026-02-09 | 13G | RA Capital Healthcare Fund, L.P.partnership | 13.1M | 9.9% | 2026-02-02 |
| 2026-02-09 | 13G | RA Capital Management, L.P.investment adviser, partnership | 13.1M | 9.9% | 2026-02-02 |
| 2026-02-09 | 13G | Peter Kolchinskyparent holding company, individual | 13.1M | 9.9% | 2026-02-02 |
| 2026-02-09 | 13G | Rajeev Shahparent holding company, individual | 13.1M | 9.9% | 2026-02-02 |
| 2026-02-04 | 13D/Ano. 1 | Adelman Robert Jindividual | 13.0M | 9.9% | 2026-02-02 |
| 2025-11-14 | 13G/Ano. 3 | TANG CAPITAL MANAGEMENT, LLCother entity | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | KEVIN TANGindividual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | TANG CAPITAL PARTNERS, LPpartnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | TANG CAPITAL PARTNERS III, INCcorporation | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | TANG CAPITAL PARTNERS IV, INCcorporation | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding ALXO at their latest 13F. JSON3 of the 30 tracked managers held ALXO at their latest 13F, $9.0M in total at quarter-end prices. Two Sigma Investments is the largest at $4.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 2.2M | $4.5M | 0.00% | +590K |
| Millennium Management | 2026-06-30 | 1.5M | $3.2M | 0.00% | -445K |
| Renaissance Technologies | 2026-06-30 | 604K | $1.2M | 0.00% | -129K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Alx Oncology Holdings in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Alx Oncology Holdings (ALXO), SEC CIK 1810182, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-16.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-08.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1810182Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ALXO is sold short?
5,976,398 shares were held short at the 2026-10-15 settlement, 3.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ALXO's daily short volume?
On 2026-11-03, 180,765 of the 266,567 ALXO shares reported to FINRA were sold short, 67.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ALXO have fails to deliver?
The SEC's latest file shows 17 ALXO shares failed to deliver at settlement 2026-09-17. Fails are reported per settlement date and published twice a month with a lag.
Are ALXO insiders buying or selling?
Insiders at ALXO reported 2 open-market sells worth $5K in the last 90 days and no open-market buys. Latest filing: Lettmann Jason (CHIEF EXECUTIVE OFFICER) on 2026-08-17.
Who owns 5% or more of ALXO?
13 holders report 5% or more of ALXO in their latest filing, 5 on Schedule 13D (active intent). The largest reported stake is GOODMAN COREY S at 10.0% of the class (12,927,442 shares), filed 2026-10-16 for an event on 2026-10-14.
Which tracked 13F managers own ALXO?
3 of the 30 tracked 13F managers held ALXO shares at their latest filing, $9.0M in all. The largest: Two Sigma Investments (2.2M shares, $4.5M), Izzy Englander's Millennium Management (1.5M shares, $3.2M), Renaissance Technologies (604K shares, $1.2M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.